Therapeutic vesicles and methods of treatment thereof

By contacting the surfactant, the drug loading efficiency of extracellular vesicles is improved, and the problems of low loading efficiency and high toxicity in the prior art are solved, and more efficient delivery of therapeutic agents is achieved.

CN118946345APending Publication Date: 2024-11-12SILOCELL BIOTECH HONG KONG LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380029263.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-22
Filing Date
2023-03-22
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing extracellular vesicles (EVs) as drug delivery vehicles have low loading efficiency and potential toxicity problems, resulting in poor efficacy.

Method used

Extracellular vesicles loaded with cargo are obtained by contacting biological samples with cargo molecules and surfactants to form a solution of detergent mixture, and after removal of detergent, the cargo is obtained by using nonionic surfactants such as Triton X-100 or octaglycol monochloride Dialkyl ethers improve the loading efficiency of vesicles.

Benefits of technology

It significantly improves the drug loading efficiency of extracellular vesicles, reduces side effects, and achieves more efficient delivery of therapeutic agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946345A_ABST
    Figure CN118946345A_ABST
Patent Text Reader

Abstract

The present specification discloses extracellular vesicles and methods of making extracellular vesicles in the presence of a detergent.
Need to check novelty before this filing date? Find Prior Art

Description

Cross-references

[0001] This application claims priority to the international application No. PCT / CN2022 / 082187 filed on March 22, 2022, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present disclosure relates to therapeutic vesicles and methods of processing the same. Background Art

[0003] Extracellular vesicles (EVs) are naturally occurring extended particles secreted by cells and present in most organisms. Recently, it has been discovered that important biological functions of EVs include facilitating intercellular communication processes by acting as cargo aggregates for the transport of important cellular components, such as soluble proteins or active enzymes, lipids, and nucleic acids, such as mRNAs, microRNAs, long noncoding RNAs, and metabolites. This transport capacity of EVs has prompted the exploration of using EVs to deliver agents, such as therapeutic agents, to or within target cells.

[0004] Compared with other well-known synthetic drug delivery vehicles (such as liposomes, lipid nanoparticles or viral vectors), EVs offer many advantages as drug carriers due to their characteristics: i) they are naturally secreted from cells and can communicate between cells over short or long distances; ii) they are expected to have tropism for specific organs or cells by binding to specific surface receptors; iii) they have higher cargo transport efficiency due to multiple cellular uptake pathways, which may include endocytosis, phagocytosis, microphagy or direct fusion with the receptor cell membrane; and iv) they can avoid immune clearance due to the intrinsic nature of the carrier.

[0005] However, despite the above advantages, currently available EVs still have many disadvantages as drug delivery vehicles, involving potential toxicity and low loading efficiency, ultimately leading to low efficacy. In particular, known strategies for active loading of EVs include electroporation, ultrasound, freeze-thaw, and chemical-assisted loading, each of which suffers from chemical or biological toxicity and low loading efficiency.

[0006] Therefore, there is a need in the art to provide improved EVs conjugation methods to produce EVs with superior loading capacity and reduced side effects for the delivery of therapeutic agents or any molecules of interest. Summary of the invention

[0007] The present specification discloses a method for producing extracellular vesicles. The present specification also discloses a kit for producing extracellular vesicles using at least one detergent and one or more detergent removers.

[0008] In some embodiments, the present specification provides a method for processing EVs. The method comprises the following steps: contacting a biological sample containing a plurality of extracellular vesicles with a cargo molecule and a detergent to form a detergent mixture solution; and removing the detergent from the detergent mixture solution to obtain a plurality of extracellular vesicles loaded with cargo.

[0009] In some embodiments, the biological sample containing extracellular vesicles can be contacted with the cargo molecule and the detergent by adding the cargo molecule and the detergent simultaneously. In some embodiments, the biological sample containing extracellular vesicles can be contacted with the cargo molecule and the detergent by adding the cargo molecule and the detergent sequentially. In some embodiments, the method includes the step of contacting the biological sample containing multiple EVs with the cargo molecule and the detergent by adding the cargo molecule before adding the detergent. In other embodiments, the method includes the step of contacting the biological sample containing multiple EVs with the cargo molecule and the detergent by adding the detergent before adding the cargo molecule.

[0010] In some embodiments, the detergent comprises a surfactant. In some embodiments, the surfactant is a nonionic surfactant. In some embodiments, the surfactant comprises a hydrophilic group and a hydrophobic group. In some embodiments, the hydrophilic group of the surfactant comprises a polyethylene oxide chain. In some embodiments, the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol. In some embodiments, the surfactant is dodecyl octanediol or octaethylene glycol monododecyl ether.

[0011] In some embodiments, the cargo molecule comprises an active pharmaceutical ingredient (API). In some embodiments, the cargo molecule comprises a small molecule therapeutic drug. In some embodiments, the cargo molecule comprises a polypeptide, a protein, a lipid, a nucleic acid, a carbohydrate, a lipid, a metabolite, or any combination thereof. In some embodiments, the nucleic acid comprises DNA. In some embodiments, the nucleic acid comprises a peptide nucleic acid (PNAs). In some embodiments, the nucleic acid comprises RNA. In some embodiments, the RNA is selected from the group consisting of mRNA, small interfering RNA (siRNA), short hairpin RNA (shRNA), piwi interacting RNA (piRNA), small nucleolar RNAs (snoRNAs), antisense RNA, micro RNA (mi-RNA) and long non-coding RNA (lncRNA). In some embodiments, the protein comprises an antibody or an enzyme. In some embodiments, the cargo molecule comprises an antisense oligonucleotide. In some embodiments, the cargo molecule comprises a morpholino oligomer. In some embodiments, the cargo molecule comprises one or more components of a gene editing system. In some embodiments, the gene editing system is selected from the group consisting of CRISPR / Cas, zinc finger nucleases, and transcription activator-like effector nucleases (TALENs).

[0012] In some embodiments, the plurality of extracellular vesicles comprises exosomes, microvesicles, apoptotic bodies or any combination thereof. In some preferred embodiments, the plurality of extracellular vesicles comprises exosomes. In some embodiments, the detergent is removed from the detergent mixture solution using dialysis or ultracentrifugation. In some embodiments, the detergent is removed from the detergent mixture solution by contacting the detergent mixture solution with a detergent remover. In some embodiments, the detergent remover comprises a non-polar polymer adsorbent. In some embodiments, the non-polar polymer adsorbent comprises polystyrene beads. In some embodiments, the non-polar polymer adsorbent comprises SM-2 resin.

[0013] In some embodiments, the method for treating EVs further comprises obtaining the plurality of extracellular vesicles from a cell culture medium. In some embodiments, the cell culture medium is derived from growing a plurality of cultured cells. In some embodiments, the plurality of cultured cells comprises stem cells, human embryonic kidney 293 (HEK 293) cells, HEK 293T cells, or any combination thereof. In some embodiments, stem cells comprise keratinocyte stem cells. In some embodiments, the method for treating EVs further comprises purifying the plurality of extracellular vesicles by centrifugation.

[0014] In some embodiments, the present specification provides a kit for treating extracellular vesicles, the kit comprising the detergent and detergent remover described in some embodiments of the present specification. In some embodiments, the kit further comprises the cargo molecule.

[0015] In some embodiments, a composition is provided, comprising a plurality of cargo-loaded extracellular vesicles as described in some embodiments of this specification. In some embodiments, the composition further comprises a pharmaceutically acceptable excipient. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The novel features of some embodiments of the present specification are specifically described in the appended claims. The features and advantages of some embodiments of the present specification can be better understood by referring to the following detailed description and drawings, which describe illustrative embodiments utilizing the principles of the present invention:

[0017] Figure 1 Figure 2 is a flow chart of an exemplary exosome production and purification protocol using HEK293F or keratinocyte conditioned medium.

[0018] Figures 2A-2C Physicochemical properties of keratinocyte-derived exosomes are shown. Figure 2A-2B Electron microscopy images of exosome samples are shown to confirm the morphology and size of exosomes. Figure 2C A plot of concentration versus particle hydrodynamic size is shown.

[0019] Figures 3A-3C The physicochemical properties of HEK293F-derived exosomes are shown. Figure 3A-3B Electron microscopy images of exosome samples are shown to confirm the morphology and size of exosomes. Figure 3C Concentration and particle hydrodynamic size are shown.

[0020] Figures 4A-4D An exemplary exosome cargo loading process in the presence or absence of detergent is shown. Figure 4A Schematic diagram of the exosome loading process. Figure 4B is an overview of exosome cargo loading. Figure 4C is the chemical structure of an exemplary detergent Triton X-100. Figure 4D is the chemical structure of the exemplary detergent octaethylene glycol monododecyl ether (C12E8).

[0021] Figure 5 A bar graph of FITC-dextran loading efficiency is shown. The loading efficiency of FITC-dextran into exosomes was measured using nanoflow cytometry with or without the addition of detergent (Triton X-100).

[0022] Figures 6A-6C A schematic diagram of the exosome lysis and reconstitution process is shown. Fig. 6A Schematic diagram of the dissolution of keratinocyte-derived EVs in response to increasing concentrations of Triton X-100. Figure 6B Schematic diagram of the dissolution of HEK293F-derived EVs with increasing Triton X-100 concentrations. Figure 6C The exosome dissolution curves were measured by nano-flow cytometry with increasing addition of Triton X-100 (dot, woB) to measure the change in particle concentration. Figure 6C ). This specification also illustrates the reconstitution of exosomes after addition of bio-beads and extraction with Triton X-100 (square, wB).

[0023] Figure 7 A bar graph showing the loading efficiency of FAM-labeled siRNA was shown. The loading efficiency of FAM-labeled siRNA in exosomes under different conditions was measured using nanoflow cytometry (such as loading exosomes by incubation, electroporation or detergent-assisted method).

[0024] Figures 8A-8B Bar graph showing the loading efficiency of Cy5-labeled siRNA in the presence or absence of octaethylene glycol monododecyl ether (C12E8). Fig. 8A Bar graph showing the loading efficiency of Cy5-labeled siRNA in HEK293F-derived EVs. Figure 8B Bar graph showing the loading efficiency of Cy5-labeled siRNA in keratinocyte-derived EVs. DETAILED DESCRIPTION

[0025] Disclosed herein are purified extracellular vesicles (EVs) that have been engineered to incorporate sufficient amounts of one or more therapeutic agents or any related molecules, and a method of using EVs to deliver an effective amount of a therapeutic agent or any related molecule to a target site. definition

[0026] The term "about" and its grammatical equivalents in relation to a reference value and its grammatical equivalents may include a numerical range of plus or minus 10% from the numerical value, such as a numerical range of plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from the numerical value. For example, the number "about 10" includes numbers from 9 to 11. Unless otherwise stated, some embodiments of the present specification contemplate numerical ranges. When a numerical range is provided, unless otherwise stated, the range includes the range endpoints. Unless otherwise stated, a numerical range includes all values ​​and subranges therein as if explicitly written.

[0027] As used herein, the singular forms "a", "an" and "an" include plural references unless the context clearly dictates otherwise. Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification are approximations that may vary depending upon the desired properties sought to be obtained by the specification.

[0028] Unless otherwise stated, open ended terms such as "comprising," "including," "comprising," etc., are intended to be inclusive.

[0029] The terms "agent", "active pharmaceutical ingredient (API)", "therapy", "therapeutic agent" and "drug" are used interchangeably and include an agent that has a pharmacological effect, wherein the pharmacological effect includes inducing a biological or medical response in an animal or human tissue or cell system desired by a researcher, veterinarian, general practitioner or other physician, changing a biological system at the molecular level (e.g., as an inhibitor, activator or modulator of a protein), alleviating or treating symptoms or a disease or disorder; the agent can be a chemical compound, a biological molecule with therapeutic activity (such as siRNAs, miRNAs, anti-miRNAs, shRNAs, etc., antibodies, antibody fragments that recognize specific epitopes), an anti-tumor drug or a radiotherapeutic drug.

[0030] The term "biological sample" refers to any sample obtained from or otherwise derived from a biological entity such as an animal. Examples of biological samples include cells, tissues, organ tissue samples obtained from in vitro cell or tissue culture or in vivo. Non-limiting specific examples of biological samples include cytology samples, tissue samples, biological fluids, blood, urine, pre-ejaculatory fluid, nipple aspirate, semen, milk, sputum, mucus, pleural effusion, pelvic effusion, synovial effusion, ascites, body cavity washes, eye brushes, skin scrapings, oral swabs, vaginal swabs, cervical smears, rectal swabs, aspirates, needle biopsies, tissue sections obtained by, for example, surgery or autopsy, etc., plasma, serum, cerebrospinal fluid, lymphatic fluid, sweat, tears, saliva, tumors, or any suitable sample from a biological entity therein.

[0031] The term "cargo molecule" refers to any molecule or compound that has been or will be incorporated, encapsulated, fused or injected into a transfer cargo (such as a vesicle, exosome, etc.) molecule, which can be a chemical molecule or a biological molecule with or without therapeutic activity.

[0032] The terms "detergent" and "surfactant" are used interchangeably herein to describe a compound consisting of a lipophilic and a hydrophilic segment that, when added to water or a solvent, reduces the surface tension of the system. The term "nonionic detergent" refers to a detergent molecule that contains an uncharged hydrophilic head group.

[0033] The term "extracellular vesicle" should be understood as generally known in the art, referring to a vesicle containing a membrane-enclosed cytoplasmic portion released from cells in the microenvironment. These vesicles represent a heterogeneous population consisting of multiple types of vesicles, including "exosomes" and microvesicles or apoptotic bodies, which can be distinguished by size, antigen composition and secretion pattern. The terms "therapeutic delivery vesicle" and "therapeutic cargo" should be understood to refer to any type of vesicle, such as a vesicle that can be obtained from a cell, such as a microvesicle (any vesicle shed from the cytoplasmic membrane), an exosome (any vesicle obtained from the endolysosomal pathway), an apoptotic body (from an apoptotic cell), a microparticle (obtainable from, for example, platelets), an extranuclear granule (obtainable from, for example, neutrophils and monocytes in serum), a prostatic body (extractable from prostate cancer cells), a cardiostatic body (obtainable from heart cells), etc. In addition, the terms "vesicles transporting cargo molecules" and "transport vesicles" should also be understood as possibly related lipoprotein particles, such as LDL, VLDL, HDL and chylomicrons, as well as liposomes, lipidoid particles, lipidoids, etc. In essence, the present description may relate to any type of lipid-based structure (vesicle or having any other type of appropriate morphology) that can serve as a delivery or transport vehicle for cargo molecules.

[0034] The term "loading" or "loading of extracellular vesicles" is understood in this specification as an activity or state, as a result of which the vesicle interior, the vesicle and / or the vesicle membrane surface contain one or more related molecules that are not normally present.

[0035] The terms "purified" or "isolated" are used interchangeably to mean free from its natural environment. "Purified" or "isolated" does not require absolute purity or isolation; rather, it is a relative term.

[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the formulations or unit doses herein, certain methods and materials are now described. Unless otherwise indicated, the techniques used or contemplated for use herein are standard methods. The materials, methods, and examples are for illustration only and are not intended to be limiting. Methods for producing extracellular vesicles (EVs)

[0037] The present specification discloses EVs containing at least one cargo molecule. The present specification also discloses a method for manufacturing EVs for loading sufficient amounts of one or more cargo molecules so as to deliver appropriate amounts of one or more cargo molecules to or within relevant target cells or tissues.

[0038] In some embodiments, the present specification provides a method for processing extracellular vesicles (EVs), the method comprising the following steps: contacting a biological sample containing multiple extracellular vesicles with cargo molecules and a detergent to form a detergent mixture solution; and removing the detergent from the detergent mixture solution to obtain multiple extracellular vesicles loaded with cargo.

[0039] The cargo molecule in this specification may be any compound, molecule or peptide with or without biological activity. In some embodiments, the cargo molecule includes an active pharmaceutical ingredient (API). In some embodiments, the cargo molecule may be a therapeutic agent. The therapeutic agent in this specification may be a compound, such as an anti-tumor drug, a radiotherapy drug, an antibiotic, or a biomolecule with therapeutic activity (such as siRNAs, miRNAs, anti-miRNAs, shRNAs, etc., antibodies, antibody fragments, peptides, etc.). In some embodiments, the cargo molecule includes a polypeptide, a protein, a lipid, a nucleic acid, a metabolite, or any combination thereof. In some embodiments, the nucleic acid is selected from a group consisting of DNA, mRNA, small interfering RNA (siRNA), microRNA (mi-RNA), and long non-coding RNA (lncRNA). Other exemplary cargo molecules include, but are not limited to, proteins, carbohydrates, lipids, small molecule therapeutic drugs, toxins, antibodies, recombinant proteins, viral vectors, vaccines, antisense oligonucleotides, gene editing systems (such as CRISPR / Cas9 systems), or any combination thereof.

[0040] In some embodiments, the final concentration of one or more cargo molecules is about 0.1 μM to 300 μM. In some embodiments, the final concentration of one or more cargo molecules is at least about 0.1 μM to 1 μM, about 0.1 μM to 10 μM, about 0.1 μM to 20 μM, about 0.1 μM to 50 μM, about 0.1 μM to 100 μM, about 0.1 μM to 150 μM, about 0.1 μM to 200 μM, about 0.1 μM to 300 μM, about 1 μM to 10 μM, about 1 μM to 20 μM, about 1 μM to 50 μM, about 1 μM to 100 μM, about 1 μM to 150 μM, about 1 μM to 200 μM, about 1 μM to 300 μM, about 10 μM to 20 μM, about 10 μM to 50 μM, About 10μM to 100μM, about 10μM to 150μM, about 10μM to 200μM, about 10μM to 300μM, about 20μM to 50μM, about 20μM to 100μM, about 20μM to 150μM, about 20μM to 200μM, about 20μM to 300μM, about 50μM to 100μM, about 50μM to 150μM, about 50μM to 200μM, about 50μM to 300μM, about 100μM to 150μM, about 100μM to 200μM, about 100μM to 300μM, about 150μM to 300μM, or about 200μM to 300μM. In some embodiments, the total concentration of one or more cargo molecules is at least about 0.1 μM, about 1 μM, about 10 μM, about 20 μM, about 50 μM, about 100 μM, about 150 μM, about 200 μM, or about 300 μM.

[0041] In some embodiments, a biological sample containing multiple EVs is contacted with a detergent to form a detergent mixture solution. In some embodiments, the detergent includes a surfactant. In these embodiments, the surfactant includes a hydrophilic group and a hydrophobic group. In some embodiments, the hydrophilic group of the surfactant includes a polyethylene oxide chain. In some embodiments, the surfactant is a non-ionic surfactant. Exemplary non-ionic detergents (or surfactants) in the detergent mixture solution include, but are not limited to, BigCHAP (N,N-bis[3-(D-glucosylamino)propyl]choline), bis(polyethylene glycol bis[imidazole carbonyl]), 30(L4 polyoxyethylene lauryl ether), 35(Polyoxyethylene (23) lauryl ether), 52 (polyoxyethylene (2) hexadecyl ether), 56(polyoxyethylene (10) hexadecyl ether), 58 (polyoxyethylene (20) cetyl ether), 72 (polyoxyethylene (2) stearyl ether), 76 (polyoxyethylene (10) stearyl ether), 78 (polyoxyethylene (20) stearyl ether), 92(polyoxyethylene (2) oleyl ether), 97(polyoxyethylene (10) oleyl ether), 98(polyoxyethylene (20) oleyl ether), 700 (polyoxyethylene (100) stearyl ether), EL (castor oil / ethylene oxide polyether), decaethylene glycol monododecyl ether, caprylyl-N-methyl glucamide (MECA-8), caprylyl-N-methyl glucamide (MECA-10), n-octyl glucoside, n-dodecyl glucoside, isotridecyl poly (ethylene glycol ether) n, N-decyl-N-methyl glucamine, n-decyl-α.-D-glucopyranoside, decyl-β-D-maltopyranoside, n-dodecyl-N-methyl glucamide, n-dodecyl-α-D-maltoside, n-dodecyl-β-D-maltoside, heptaethylene glycol monododecyl ether, heptaethylene glycol monotetradecyl ether, n-hexadecyl-β-D-maltoside, hexaethylene glycol monododecyl ether, hexaethylene glycol monohexadecyl ether, hexaethylene glycol monooctadecyl ether, hexaethylene glycol monotetradecyl ether, CA-630 (octylphenyl polyethylene glycol), CA210 (polyoxyethylene (2) isooctylphenyl ether), CA-520 (polyoxyethylene (5) isooctylphenyl ether), CO630 (polyoxyethylene (9) nonylphenyl ether), CO-720 (polyoxyethylene (12) nonylphenyl ether), CO-890 (polyoxyethylene (40) nonylphenyl ether), CO-990 (polyoxyethylene (100) nonylphenyl ether), DM-970 (polyoxyethylene (150) dinonylphenyl ether), methyl-6-oxy-(N-heptylcarbamoyl)-.α.-D-pyranoglucoside, nonaethylene glycol monododecyl ether, N-nonanoyl-N-methylglucosamine, octaethylene glycol monododecyl ether, octaethylene glycol monohexadecyl ether, octaethylene glycol monooctadecyl ether, octaethylene glycol monotetradecyl ether, octyl-β-D-pyranoglucoside, pentaethylene glycol monodecyl ether, pentaethylene glycol monododecyl ether, pentaethylene glycol monodecyl ether Hexadecyl ether, pentaethylene glycol monohexyl ether, pentaethylene glycol monooctadecyl ether, pentaethylene glycol monooctyl ether, polyethylene glycol diglycidyl ether, polyethylene glycol ether W-1, polyoxyethylene (10) tridecanol ether, polyoxyethylene (100) stearate, polyoxyethylene (20) isohexadecanol ether, polyoxyethylene (20) oleyl ether, polyoxyethylene (40) stearate, polyoxyethylene (50) stearate, polyoxyethylene (8) stearate, polyoxyethylene bis (imidazole carbonyl) ether, polyoxyethylene (25) propylene glycol stearate, saponin, 20(Sorbitan monolaurate), 40(sorbitan monopalmitate), 60(sorbitan monostearate), 65(sorbitan tristearate), 80(sorbitan monooleate), 85 (sorbitan trioleate), any form of Tergitol (including 15-S-5, 15-S-7, 15-S-9, 15-S-12, 15-S-30, NP-4, NP-7, NP-9, NP-10, NP-40, NPX (Imbentin-N / 63), TMN-3 (polyethylene glycol trimethyl nonyl ether), TMN-6 (polyethylene glycol trimethyl nonyl ether), TMN-10 (polyethylene glycol trimethyl nonyl ether), MIN FOAM 1x and MIN FOAM 2x), tetradecyl-β-D-maltoside, tetraethylene glycol monodecyl ether, tetraethylene glycol monododecyl ether, tetraethylene glycol monotetradecyl ether, triethylene glycol monodecyl ether, triethylene glycol monododecyl ether, triethylene glycol monohexadecyl ether, triethylene glycol monooctyl ether, triethylene glycol monotetradecyl ether, CF-21, CF-32, DF-12, DF-16, GR5M, N-1 01 (polyoxyethylene branched nonylphenyl ether), QS-15, QS-44, RW-75 (polyethylene glycol 260 mono(hexadecyl / octadecyl) ether and 1-octadecyl alcohol), X-100 (polyethylene glycol tert-octylphenyl ether), X-102, X-15, X-151, X-200, X-207, X-114, X-165, X-305, X-405 (polyoxyethylene (40) isooctylphenyl ether), reduced type X-405 (polyoxyethylene (40) isooctyl cyclohexyl ether), X-45 (polyethylene glycol 4-tert-octylphenyl ether), X-705-70, any form (include 20(polyoxyethylene sorbitan monolaurate)), 21(polyoxyethylene sorbitan monolaurate), 40(polyoxyethylene (20) sorbitan monopalmitate), 60 (polyethylene glycol sorbitan monostearate), 61(Polyethylene glycol sorbitan monostearate), 65 (polyoxyethylene sorbitan tristearate), 80(polyoxyethylene sorbitan monooleate), 81 (polyoxyethylene sorbitan monooleate), and 85 (polyoxyethylene (20) sorbitan trioleate)), tyloxapol (polymer of 4-(1,1,3,3-tetramethylbutyl)phenol with formaldehyde and ethylene oxide) and n-undecyl β-D-pyranoglucoside. In some embodiments, the detergent is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol. In some embodiments, the detergent is dodecyl octanediol or octaethylene glycol monododecyl ether. In some embodiments, the detergent is octaethylene glycol monododecyl ether.

[0042] In addition, other detergents can be added to the detergent mixture solution containing the non-ionic detergent. The other detergent can be an anionic detergent. Exemplary anionic detergents include chenodeoxycholic acid, cholic acid, dehydrocholic acid, deoxycholic acid, digitonin, digitoxin, dodecyldimethylamine oxide, sodium docusate, sodium glycochenodeoxycholate, glycocholic acid, glycodeoxycholic acid, glycolithocholic acid 3-sulfate disodium salt, glycolithocholic acid ethyl ester, N-lauroylsarcosine, lithium dodecyl sulfate, Lugol (potassium iodide iodide), Niaproof (2-ethylhexyl sulfate sodium salt), Niaproof 4 (7-ethyl-2-methyl-4-undecyl sulfate sodium salt), optionally substituted alkyl sulfonates (including 1-butane sulfonate, pentane sulfonate, hexane sulfonate, 1-octane sulfonate, 1-decane sulfonate, 1-dodecane sulfonate, 1-heptane sulfonate, 1-nonane sulfonate, 1-propane sulfonate and 2-bromoethane sulfonate, especially the sodium salt), sodium cholate, sodium deoxycholate, optionally substituted sodium dodecyl sulfate, sodium octyl sulfate, sodium taurocholate, sodium taurochenodeoxycholate, sodium taurohyodeoxycholate, taurolithocholic acid 3-sulfate disodium salt, tauroursodeoxycholic acid sodium salt, dodecyl sulfate, ursodeoxycholic acid. Anionic detergents may be provided in the form of an acid or a salt, or in the form of a combination of the two. Exemplary cationic detergents include alkyl trimethylammonium bromide, benzalkonium chloride, benzyl dimethyl hexadecyl ammonium chloride, benzyl dimethyl tetradecyl ammonium chloride, benzyl dodecyl dimethyl ammonium bromide, benzyl trimethyl ammonium tetrachloroiodate, dimethyl octadecyl ammonium bromide, dodecyl dimethyl ammonium bromide, dodecyl trimethyl ammonium bromide, hexadecyl dimethyl ethidium bromide, Girard's reagent T, hexadecyl trimethyl ammonium bromide, N, N', N'-polyoxyethylene (10)-N-tallow-1,3-diaminopropane, pine ammonium bromide, and trimethyl (tetradecyl) ammonium bromide. Exemplary zwitterionic detergents include CHAPS (3-{(3-cholamidopropyl)-dimethylammonium}-1-propane sulfonate), CHAPSO (3-{(3-cholamidopropyl)dimethylammonium}-2-hydroxy-1-propane sulfonate), 3-(decyldimethylammonium)propane sulfonate, 3-(dodecyldimethylamino)propane sulfonate, 3-(N,N-dimethylmyristylammonium)propane sulfonate, 3-(N,N-dimethyloctadecylamino)propane sulfonate, 3-(N,N-dimethyloctylamino)propane sulfonate, and 3-(N,N-dimethylpalmitylamino)propane sulfonate. Other exemplary detergents include, but are not limited to, octyl glucoside, octylphenoxypoly(ethyleneoxy)ethanol ( P-40) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). Combinations of two or more detergents are also contemplated, as are combinations of one or more detergents and one or more other lipid compounds.

[0043] In some embodiments, the one or more detergents have low or no toxicity to cells. In some embodiments, the detergent is a non-ionic detergent. In these embodiments, the detergent is polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether (Triton ). In some embodiments, the detergent is octaethylene glycol monododecyl ether (OEG). In some embodiments, the EV comprises polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether at a final concentration of about 0.03mM to 4mM, about 0.04mM to 3mM, about 0.05mM to 2.5mM, about 0.06mM to 2.2mM, about 0.08mM to 2mM, about 0.1mM to 1.8mM, about 0.2mM to 1.5mM, or any concentration therebetween.

[0044] In some embodiments, a biological sample comprising a plurality of EVs may form a detergent mixture solution having a final detergent concentration of about 0.005% v / v to 10% v / v, about 0.01% v / v to 9.8% v / v, about 0.02% v / v to 9.6% v / v, about 0.04% v / v to 9.4% v / v, about 0.06% v / v to 9.2% v / v, about 0.08% v / v to 9.0%, about 0.1% v / v to 8.0% v / v, about 0.1% v / v to 7.0% v / v, about 0.1% v / v to 6.0% v / v, about 0.1% v / v to 8.0% v / v. v~5.0% v / v, about 0.2% v / v~4.0% v / v, about 0.4% v / v, about 0.5% v / v, about 0.6% v / v, about 0.8% v / v, about 1.0%, about 1.2%, about 1.4%, about 1.6%, about 1.8%, about 2.0%, about 2.2%, %, about 2.4%, about 2.6%, about 2.8%, about 3.0%, about 3.2%, about 3.4%, %, about 3.6%, about 3.8%, about 4.0%, about 4.2%, about 4.4%, about 4.6%, about 4.8%, about 5.0% or any concentration in between.

[0045] In some embodiments, a biological sample containing extracellular vesicles can be contacted with a cargo molecule and a detergent by adding the cargo molecule and the detergent simultaneously. In some embodiments, a biological sample containing extracellular vesicles can be contacted with a cargo molecule and a detergent by adding the cargo molecule and the detergent sequentially. In some embodiments, the method includes the steps of contacting a biological sample containing multiple EVs with a cargo molecule and a detergent by adding the cargo molecule before adding the detergent. In some other embodiments, the method includes the steps of contacting a biological sample containing multiple EVs with a cargo molecule and a detergent by adding the detergent before adding the cargo molecule.

[0046] In some embodiments, the detergent mixture solution may contain more than one non-ionic detergent to disrupt the lipid membrane structure of various types of EVs, such as virosomes or fusogenic liposomes. In these embodiments, the preferred non-ionic detergent can be any non-ionic detergent having a hydrophilic region and a hydrophobic region and / or a lipophilic region so that the lipophilic region interacts with the lipid components within the lipid membrane structure. In some embodiments, EVs can be assembled in vitro in a cell-free system, and part of their lipid membrane is derived from purified viral membrane components. Typical viruses used to assemble EVs include, but are not limited to, influenza virus, hepatitis B virus, human immunodeficiency virus, Newcastle disease virus, and Sendai virus.

[0047] In some embodiments, the detergent mixture solution is contacted with a detergent remover to obtain a plurality of cargo-loaded EVs. In these embodiments, the detergent remover comprises a non-polar polymer adsorbent. In some embodiments, the non-polar polymer adsorbent comprises polystyrene beads. Some exemplary non-polar polymer adsorbent beads include, but are not limited to, HP-20 (Mitsubishi Chemical), SP-825 (Mitsubishi), Amberlite XAD-2 and XAD-4 (manufactured by Rohm and Haas), and Duolite S-861, S-862 (Sumitomo Chemical), and SM-2 (Bio-Rad Laboratories). In some embodiments, the non-polar polymer adsorbent may be SM-2 resin.

[0048] In some embodiments, a detergent remover can be added to a purification column (e.g., a chromatography column) for a larger volume of EVs loading process. In these embodiments, the purification column can be filled with an appropriate amount (e.g., 10-100% w / w, 20-100% w / w, 30-100% w / w, 40-100% w / w, 50-100% w / w, 60-100% w / w, 70-100% w / w, 80-100% w / w, etc.) of detergent remover. In some embodiments, the purification column is filled with SM-2 resin. In some embodiments, the purification column is filled with any of the above-mentioned detergent removers. After the detergent-assisted loading process, the prepared purification column can be used to remove excess detergent from the cargo-loaded EVs.

[0049] In some embodiments, other methods can be used to remove detergents. For example, dialysis or ultracentrifugation (such as discontinuous sucrose gradient centrifugation) can be considered to remove detergents and / or other impurities after loading EVs.

[0050] On the other hand, the method for processing EV further comprises obtaining a plurality of EVs from a cell culture medium. In some embodiments, the cell culture medium is used to culture a plurality of cultured cells. In some embodiments, the plurality of cultured cells comprises stem cells, human embryonic kidney 293 (HEK 293) cells, HEK 293T cells, or any combination thereof. In some embodiments, the stem cells comprise keratinocyte stem cells.

[0051] In some embodiments, the biological sample can be a purified cell culture medium. In other embodiments, the biological sample can be an unpurified cell culture medium. A biological sample containing multiple vesicles can be filtered through a filter with a suitable mesh or pore size (such as a nylon mesh cell filter). The pore size of the filter may be 50nm to 100nm. In some embodiments, the pore size of the filter may be 80nm to 90μm. In some embodiments, the pore size of the filter may be 100nm to 80μm. In some embodiments, the filter may have a pore size of about 200nm to 70μM, about 400nm to 60μM, about 600nm to 50μM, about 800nm ​​to 40μM, or about 1μM to 20μM. In some embodiments, the method for processing EVs further includes purifying multiple extracellular vesicles by centrifugation.

[0052] In some embodiments, multiple EVs can be purified or isolated from cells, cell culture media, or tissues as described in Example 1. In some embodiments, multiple EVs can be purified or isolated prior to contact with a detergent or cargo molecule. In some embodiments, multiple EVs can be purified or isolated after contact with a detergent removal agent. In some embodiments, EVs can be purified or isolated into multiple cargo-loaded EVs.

[0053] In some embodiments, the EV has an average diameter length of at least about 80 nm. In some embodiments, the EV has an average diameter length of at least about 180 nm. In some embodiments, the average diameter length of the EV is at least about 80 nm to 180 nm, about 85 nm to 175 nm, about 90 nm to 160 nm, about 92 nm to 150 nm, about 96 nm to 140 nm, about 98 nm to 130 nm, about 100 nm to 120 nm, about 102 nm to 112 nm, or about 105 nm to 110 nm. After loading with cargo molecules, the size of the EV may change. In some other embodiments, the size of the EV may remain unchanged after loading.

[0054] On the other hand, the present specification also provides a kit for treating EV, the kit comprising a detergent and a detergent remover as described above. In some embodiments, the kit further comprises a cargo molecule of the present specification.

[0055] In some embodiments, the methods of the present specification can provide an active pharmaceutical ingredient (API) loading efficiency of at least about 1% to 40%, for example, at least about 5% to 40%, at least about 10% to 40%, or at least about 15% to about 40%, about 1%, about 2%, about 4%, about 6%, about 8%, about 10%, about 12%, about 14%, about 16%, about 18%, about 20%, about 22%, about 24%, about 26%, about 28%, about 30%, about 32%, about 34%, about 36%, about 38% or about 40%, including any value or range therebetween. In some embodiments, the method of the present specification provides an API loading efficiency of about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or about 100%, including any value or range therebetween. In some embodiments, the method can provide an API loading efficiency (%) of at least about 20% or about 25%. In some embodiments, the method can provide an API loading efficiency (%) of about 30% or about 40%. In some embodiments, the method provides an API loading efficiency of about 30-50%. Methods of using EVs

[0056] The present description provides a method of using the EVs herein to treat a patient with a chronic and recurring disease by administering an effective dose of the EVs to the patient. The chronic and recurring disease can be diabetes, infection, protein deficiency, or immune disorder.

[0057] In the treatment methods of the present specification, EV can be administered to the patient via intravenous, intraarterial, intranasal or topical administration. The effective dose can be empirically assessed by the attending physician or set for each condition through in vivo or in vitro assessment. Example

[0058] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Those skilled in the art may make changes and substitutions to the present invention without departing from the present invention. It should be understood that various alternatives to the embodiments described herein may be employed in practicing the present invention. The following claims are intended to define the scope of the present invention and are intended to cover methods and structures within the scope of these claims and their equivalents. Example 1. Method for isolating and purifying exosomes from mammalian cells

[0059] refer to Figure 1 , a flow chart outlining the differential centrifugation method for isolating and purifying exosomes from various mammalian cell types.

[0060] Briefly, exosomes were produced from the conditioned media of several cultured cell lines, including keratinocyte stem cells and HEK 293T cells. 293T cells were cultured in DMEM supplemented with 10% fetal bovine serum and incubated at 37°C with 5% CO. 2 Keratinocyte stem cells were cultured in EpiZero medium. For exosome purification, the fetal bovine serum was replaced with an exosome-depleted serum. Exosomes in the supernatant of keratinocyte culture medium were directly purified without replacing the serum with exosome-depleted serum.

[0061] Keratinocyte stem cells or 293T cells were cultured at 4 × 10 6 or 3×10 6 The cells were seeded at a density of 175-cm 2 flasks for 5 days. The cell culture supernatant was collected in a 50-mL centrifuge tube and immediately centrifuged in two steps at 300 x g for 10 min and 2000 x g for 10 min at 4°C, followed by 0.22-μm membrane filtration to remove cells, cell debris, shed vesicles, and other debris. At each step, the supernatant was carefully transferred to a new tube. The exosome fraction was placed in a 38.5-mL polypropylene centrifuge tube and ultracentrifuged at 100,000 x g for 85 min at 4°C in a SW32Ti rotor. The pellet was rinsed with 12.5 mL PBS and then ultracentrifuged a second time at 100,000 x g for 85 min at 4°C. Finally, the supernatant was discarded and the EVs were resuspended in 100 μL PBS. Exosomes collected from the 293T cell culture supernatant were analyzed by size exclusion chromatography (SEC) using a SEC column. The concentration of collected exosomes was quantified by measuring protein concentration using the BCA protein quantification assay.

[0062] The physicochemical properties of the isolated exosomes were further characterized. To observe the morphology of the isolated exosomes, exosome-containing samples and transmission electron microscopy (TEM) grids (copper) for electron microscopy were prepared at room temperature. 10 mL aliquots of the extracellular vesicle sample were dropped on the grid and then air-dried for 10 min. Excess liquid was wiped off with filter paper. The grid was then rinsed with 10 mL PBS and quickly dried with filter paper. For negative staining, 10 mL of 2% uranyl acetate was dropped on the sample grid, timed to stain for 1-3 min, and then excess liquid was blotted off with filter paper. The samples were allowed to air-dry for 10 min before imaging. TEM images were examined in a JEOL 1200EX transmission electron microscope at 100 kV, and images were acquired using a CCD camera.

[0063] like Figure 2A and 2BAs shown in the figure, the isolated exosomes showed a "disc-like" morphology with an average diameter of about 100 nm. Nanoparticle tracking analysis further confirmed that the main peak of the particle size distribution was 106 nm. By monitoring the Brownian motion of particles in the solution, the effective hydrodynamic diameter of exosomes in the water environment was measured and calculated ( Figure 2C ). Example 2. Methods for solubilizing and recombining exosomes

[0064] Figure 3A A scheme for loading exosomes with potential therapeutic cargo molecules is illustrated. The exosome membrane structure (loading aid) is made permeable by adding a non-ionic detergent. The cargo molecules (which may be chemical small molecule drugs, miRNAs, siRNAs, lncRNAs, mRNAs, proteins / peptides or other cargo molecules) are loaded onto the exosomes by incubating them with the loaded exosomes. Finally, the loading aid is extracted from the loading environment by adding hydrophobic interaction bio-beads, leaving the cargo-loaded exosomes in the reconstructed membrane structure, e.g. Figure 3B As shown. To find the optimal loading conditions, increasing amounts of Triton X-100 were first added to solubilize the exosomes. Briefly, 1-10 μg of exosomes were dispersed in PBS solutions containing Triton X-100 at concentrations of 0, 0.1, 0.2, 0.4, 0.5, 0.6, 0.8, 1.0, 5.0% v / v in a total volume of 200 μL (equivalent to 0 to 2 mM). The solutions were incubated at 4°C or 37°C for one hour, and then the samples were incubated at 4°C before characterization by nFCM or NTA. Exosome reconstitution was achieved by first solubilizing the exosomes under different Triton X-100 conditions and then adding bio-beads to extract Triton X-100 from the samples at 4°C. The reconstituted samples were analyzed by nano-flow cytometry (nFCM) or nanoparticle tracking analysis (NTA).

[0065] For nFCM analysis, exosome samples were detected on an Apogee A60 Micro Plus flow cytometer, which was developed specifically for analyzing nanoparticles. The A60-Micro-Plus instrument has three spatially separated lasers (488nm-position C, 638nm-position B, and 405nm-position A), equipped with 6 fluorescent color detectors (445 / 50, 530 / 40, 575 / 30, LWP650, 676 / 36, and LWP750) and 3 light scattering detectors (small angle light scattering detector (SALS), multi-angle light scattering detector (MALS), and low angle light scattering detector (LALS)). In some embodiments, two commercially available mixed beads were used as controls and calibration standards before or during sample measurement. Exosome samples were diluted in PBS to within the operating range of the device (maximum 3,000 times / second). To analyze the particle size and concentration of the samples, the samples were processed at a flow rate of 1.50 μL / min using 405 nm-MALS with a cutoff of 15 (instrument arbitrary value). The 405 nm-MALS PMT was monitored and always kept below 0.5, which was considered an indicator of background noise. PBS was measured between samples as an internal control and analyzed for particle concentration as an indicator of background signal levels.

[0066] In the NTA analysis, the particle size and concentration of exosomes were evaluated using the Brownian motion NanoSight NS300 system. Exosome samples were diluted with 1 mL PBS at room temperature within the operating range and then pumped into the instrument at a fixed pump rate of 15 (instrument arbitrary units). The movement of the particles was monitored and the recorded videos were analyzed using the NTA software.

[0067] The number of particles analyzed is Figure 3C The particle number is rescaled based on the particle number of the untreated sample and set to 1.0. Figures 4A-4C As shown in the figure, as the amount of Triton X-100 added increased, the exosomes were solubilized. When the concentration of Triton X-100 was 0.09mM and 0.125mM, the relative level of particle number increased, which showed that the exosomes were reconstituted in the presence of Bio-beads. Therefore, a concentration of 0.125mM Triton X-100 was used in the following loading experiments. Example 3. Detergent-assisted exosome loading with FITC-dextran

[0068] FITC-dextran loading solution was prepared at a concentration of 8 nM in PBS. The hydrodynamic diameter of FITC-dextran (weight = 40,000) was estimated to be approximately 4 nm, and FD40 was used as a macromolecular model to estimate protein mobility. 4 μg of exosomes were dispersed in 100 μL of FITC-dextran loading solution, and a certain volume of Triton X-100 stock solution (2% v / v) was added. An optimized loading condition was selected based on the solubilization and reconstitution experiments, and Triton X-100 was extracted by adding bio-beads in Eppendorf tubes after loading. The samples were then separated from the bio-beads by low-speed centrifugation and stored at 4°C before analysis by nFCM or NTA. The loading efficiency of FITC-dextran was estimated by nanoflow cytometry, where the ratio of EVs with green fluorescent signal to the total number of EVs was measured. The results are shown in Figure 5 .

[0069] See also Figures 6A-6C , the detergent-assisted reconstitution loading process increased EVs loaded with FITC-dextran by 31% compared with the incubation process, indicating that this method is capable of loading macromolecules with similar hydrodynamic size (approximately 4 nm) into EVs. Fig. 6A and 6B Shown are the solubilization of keratinocyte-derived EVs with increasing concentrations of 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (Triton X-100) and the solubilization of HEK293F cell-derived EVs with increasing concentrations of Triton X-100. Figure 6C As shown, exosome lysis in response to increasing concentrations of Triton X-100 was analyzed using nanoflow cytometry. Example 4. Method for loading fluorescent dye (FAM)-siRNA into exosomes by electroporation

[0070] 4 μg of exosomes were placed in 1X PBS and 20 pM FAM-siRNA loading solution and incubated at 4°C to achieve FAM-siRNA loading into exosomes by electroporation. Then, electroporation was performed using a Bio-Rad electroporator at 400 V, 25 μF and a pulse electroporation protocol known in the art, or using a Lonza 3D electroporator at ED120 or ED137 electroporation protocol. Similar to the loading efficiency of FITC-dextran, the loading efficiency of FAM-siRNA loaded into exosomes was measured by nanoflow cytometry, and effective loading can be observed by the conversion of the MALS signal of the exosomes to the green fluorescence signal. Example 5. Comparative analysis of detergent-assisted exosomes and electroporated exosomes

[0071] In a typical siRNA exosome loading experiment, 1 μL of 20 pM FAM-siRNA was first dispersed in 100 μL OptiMEM, and then 4 μg of the same amount of exosomes dissolved in PBS was added to a microcentrifuge tube and equilibrated at 4°C for 10 minutes. 0.8 μL of 2% (v / v) Triton X-100 was added to the system, and then the entire loading system was incubated at 4°C for 2 hours with gentle rotation. The system was then diluted by adding 900 μL 1X PBS, and 10 Bio-Beads were added to each microcentrifuge tube, and incubated at 4°C for 3 hours with gentle rotation. Another 10 Bio-Beads were added, and the microcentrifuge tubes were incubated at 4°C with rotation for 1 hour to overnight. The Bio-Beads were separated from the sample by low-speed centrifugation, and the loaded exosomes (whether further purified by SEC or not) were collected and analyzed by nFCM or NTA. The loading efficiency of the detergent-assisted process was compared with that of the incubation and electroporation process. Four different siRNA loading conditions were tested: i) a control group, incubated in electroporation buffer; ii) electroporated in electroporation buffer; iii) another control group, in detergent-assisted loading buffer without detergent; iv) in detergent-assisted loading with Triton X-100. Figure 7 As shown. Nanoflow cytometry confirmed the effective loading of FAM-siRNA into exosomes, and the positive green fluorescence signal of FAM coincided with the exosome scattering signal detected by MALS. The loading efficiency was quantified by the percentage of green fluorescence positive exosome events, the total number of exosome events measured, and the mean fluorescence intensity shift of the nanoflow cytometer compared with the non-loaded control group. Figure 7 As shown, the efficiency of FAM-siRNA loading by detergent-assisted reconstitution was more than 3 times higher than that by incubation or electroporation. Example 6. Detergent-assisted exosome loading of Cy5-siRNA

[0072] This study aimed to evaluate the loading efficiency of Cy5-siRNA in the presence or absence of octaethylene glycol monododecyl ether (C12E8). First, HEK293F or keratinocyte-derived exosomes were dispersed in Cy5-siRNA loading solution, and a certain volume of C12E8 was added from the stock solution. An optimized loading condition was selected from the solubilization and reconstitution experiments. The loading efficiency was estimated by nanoflow cytometry, in which the ratio of EVs with green fluorescence signal to the total number of EVs was measured. The results are summarized in Fig. 8A -B. Incorporation by Reference

[0073] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated herein by reference. Embodiment number of the present disclosure

[0074] Other subject matter contemplated by this specification is listed in the following numbered embodiments: 1. A method for processing extracellular vesicles, comprising: a) contacting a biological sample containing multiple extracellular vesicles with cargo molecules and a detergent to form a detergent mixture solution; b) removing the detergent from the detergent mixture solution to obtain multiple extracellular vesicles loaded with cargo. 2. According to the method of embodiment 1, the contacting the biological sample with the cargo molecule and the detergent comprises adding the cargo molecule and the detergent simultaneously or sequentially. 3. The method according to embodiment 1 or 2, wherein contacting the biological sample with the cargo molecule and the detergent comprises adding the cargo molecule before adding the detergent, or vice versa. 4. The method of any one of embodiments 1-3, wherein the detergent comprises a surfactant. 5. The method according to embodiment 4, wherein the surfactant is a nonionic surfactant. 6. The method according to embodiment 4, wherein the surfactant comprises a hydrophilic group and a hydrophobic group. 7. The method according to embodiment 6, wherein the hydrophilic group comprises a polyethylene oxide chain. 8. The method according to embodiment 4, wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol. 9. The method according to embodiment 4, wherein the surfactant is dodecyl octanediol or octaethylene glycol monododecyl ether. 10. The method of any one of embodiments 1-9, wherein the cargo molecule comprises an active pharmaceutical ingredient (API). 11. The method of any one of embodiments 1-10, wherein the cargo molecule comprises a small molecule therapeutic drug. 12. The method of any one of embodiments 1-11, wherein the cargo molecule comprises a polypeptide, a protein, a lipid, a nucleic acid, a carbohydrate, a lipid, a metabolite or any combination thereof. 13. The method of embodiment 12, wherein the nucleic acid comprises DNA. 14. The method of embodiment 12, wherein the nucleic acid comprises peptide nucleic acid (PNA). 15. The method of embodiment 12, wherein the nucleic acid comprises RNA. 16. A method according to embodiment 15, wherein the RNA is selected from the group consisting of mRNA, small interfering RNA (siRNA), short hairpin RNA (shRNA), piwi interacting RNA (piRNA), small nucleolar RNAs (snoRNAs), antisense RNA, micro RNA (mi-RNA) and long non-coding RNA (lncRNA). 17. The method of embodiment 12, wherein the protein comprises an antibody or an enzyme. 18. The method of any one of embodiments 1-17, wherein the cargo molecule comprises an antisense oligonucleotide. 19. The method of any one of embodiments 1-18, wherein the cargo molecule comprises a morpholino oligomer. 20. A method according to any one of embodiments 1-19, wherein the cargo molecule comprises one or more components of a gene editing system. 21. A method according to Example 20, wherein the gene editing system is selected from the group consisting of CRISPR / Cas, zinc finger nuclease, and transcription activator-like effector nuclease (TALEN). 22. The method according to any one of embodiments 1-21, wherein the plurality of extracellular vesicles include exosomes, microvesicles, apoptotic bodies or any combination thereof. 23. The method of embodiment 22, wherein the plurality of extracellular vesicles comprise exosomes. 24. The method of any one of embodiments 1-23, comprising removing the detergent from the detergent mixture solution using dialysis or ultracentrifugation. 25. The method of any one of embodiments 1-24, wherein removing the detergent from the detergent mixture solution comprises contacting the detergent mixture solution with a detergent removing agent. 26. The method of embodiment 25, wherein the detergent removal agent comprises a non-polar polymer adsorbent. 27. The method of embodiment 26, wherein the non-polar polymer adsorbent comprises polystyrene beads. 28. The method of embodiment 26, wherein the non-polar polymer adsorbent comprises SM-2 resin. 29. The method according to any one of embodiments 1-28 further comprises obtaining the multiple extracellular vesicles from the cell culture medium. 30. The method according to embodiment 29, wherein the cell culture medium is obtained by culturing a plurality of cultured cells. 31. The method of embodiment 30, wherein the plurality of cultured cells comprises stem cells, human embryonic kidney 293 (HEK 293) cells, HEK 293T cells, or any combination thereof. 32. The method of embodiment 31, wherein the stem cells comprise keratinocyte stem cells. 33. The method according to any one of embodiments 1-32 further comprises purifying the multiple extracellular vesicles by centrifugation. 34. A kit for processing extracellular vesicles, comprising the detergent and detergent remover described in any one of Examples 1-33. 35. The kit according to embodiment 34 further comprises a cargo molecule. 36. A composition comprising a plurality of cargo-loaded extracellular vesicles produced by any one of embodiments 1-35. 37. The composition according to Example 36 further comprises a pharmaceutically acceptable excipient.

[0075] The various embodiments described above can be combined to provide further embodiments. All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications mentioned in this specification and / or listed in the application data sheet are incorporated herein by reference in their entirety. If necessary, various aspects of the present embodiment can be modified to adopt concepts from various patents, applications, and publications to provide more embodiments.

Claims

1. A method for processing extracellular vesicles, comprising: a) contacting a biological sample containing a plurality of extracellular vesicles with a cargo molecule and a detergent to form a detergent mixture solution; as well as b) removing the detergent from the detergent mixture solution to obtain a plurality of cargo-loaded extracellular vesicles.

2. The method according to claim 1, wherein said contacting the biological sample with the cargo molecule and the detergent comprises adding the cargo molecule and the detergent simultaneously or sequentially.

3. The method according to claim 1 or 2, wherein said contacting said biological sample with said cargo molecule and said detergent comprises adding said cargo molecule before adding said detergent, or vice versa.

4. The method of any one of claims 1-3, wherein the detergent comprises a surfactant. The method according to claim 4 , wherein the surfactant is a nonionic surfactant. The method according to claim 4 , wherein the surfactant comprises a hydrophilic group and a hydrophobic group.

7. The method of claim 6, wherein the hydrophilic groups comprise polyethylene oxide chains.

8. The method of claim 4, wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol.

9. The method according to claim 4, wherein the surfactant is dodecyl octanediol or octaethylene glycol monododecyl ether.

10. The method of any one of claims 1-9, wherein the cargo molecule comprises an active pharmaceutical ingredient (API).

11. The method of any one of claims 1-10, wherein the cargo molecule comprises a small molecule therapeutic drug.

12. The method of any one of claims 1-11, wherein the cargo molecule comprises a polypeptide, a protein, a lipid, a nucleic acid, a carbohydrate, a lipid, a metabolite, or any combination thereof.

13. The method of claim 12, wherein the nucleic acid comprises DNA.

14. The method of claim 12, wherein the nucleic acids comprise peptide nucleic acids (PNAs).

15. The method of claim 12, wherein the nucleic acid comprises RNA.

16. The method of claim 15, wherein the RNA is selected from the group consisting of mRNA, small interfering RNA (siRNA), short hairpin RNA (shRNA), piwi interacting RNA (piRNA), small nucleolar RNA (snoRNA), antisense RNA, micro RNA (mi-RNA) and long non-coding RNA (lncRNA).

17. The method of claim 12, wherein the protein comprises an antibody or an enzyme.

18. The method of any one of claims 1-17, wherein the cargo molecule comprises an antisense oligonucleotide.

19. The method of any one of claims 1-18, wherein the cargo molecule comprises a morpholino oligomer.

20. The method of any one of claims 1-19, wherein the cargo molecule comprises one or more components of a gene editing system.

21. The method of claim 20, wherein the gene editing system is selected from the group consisting of CRISPR / Cas, zinc finger nuclease, and transcription activator-like effector nuclease (TALEN).

22. The method of any one of claims 1-21, wherein the plurality of extracellular vesicles comprises exosomes, microvesicles, apoptotic bodies, or any combination thereof.

23. The method of claim 22, wherein the plurality of extracellular vesicles comprises exosomes.

24. The method of any one of claims 1-23, comprising removing the detergent from the detergent mixture solution using dialysis or ultracentrifugation.

25. The method of any one of claims 1-24, wherein removing the detergent from the detergent mixture solution comprises contacting the detergent mixture solution with a detergent removing agent.

26. The method of claim 25, wherein the detergent removing agent comprises a non-polar polymer adsorbent.

27. The method of claim 26, wherein the non-polar polymer adsorbent comprises polystyrene beads.

28. The method of claim 26, wherein the non-polar polymer adsorbent comprises SM-2 resin.

29. The method of any one of claims 1-28, further comprising obtaining the plurality of extracellular vesicles from a cell culture medium.

30. The method according to claim 29, wherein the cell culture medium is obtained by culturing a plurality of cultured cells.

31. The method of claim 30, wherein the plurality of cultured cells comprises stem cells, human embryonic kidney 293 (HEK293) cells, HEK293T cells, or any combination thereof.

32. The method of claim 31, wherein the stem cells comprise keratinocyte stem cells.

33. The method of any one of claims 1-32, further comprising purifying the plurality of extracellular vesicles by centrifugation.

34. A kit for treating extracellular vesicles, comprising the detergent and detergent remover of any one of claims 1-33.

35. The kit of claim 34, further comprising the cargo molecule.

36. A composition comprising a plurality of cargo-loaded extracellular vesicles produced by any one of claims 1-35.

37. The composition of claim 36, further comprising a pharmaceutically acceptable excipient.

Citation Information

Cited By

  • Microfluidic intracellular delivery device and delivery method based on 3D electroporation system

    CN119614366A

  • A microfluidic intracellular delivery device and delivery method based on a 3D electroporation system

    CN119614366B